Wechselwirkungen · Stribild
Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-218429 · Präparat HOS-216207
Co-administration of Stribild with medicinal products that are primarily metabolised by CYP3A or CYP2D6, or are substrates of P-gp, BCRP, OATP1B1 or OATP1B3 may result in increased plasma concentrations of those products, which could increase or prolong their therapeutic effect and adverse reactions (see Concomitant use contraindicated and section 4.3). Co-administration of Stribild with medicinal products that have active metabolite(s) formed by CYP3A may result in reduced plasma concentrations of these active metabolite(s).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-23T16:51:00Z · SHA-256 d3f228ded6370d77784fda3a53beaff9f1155c63df0f682c7673ee3cdc2ccdc5 · Passage 3ddecb5c67f4275d27a7ccfe3924ff5ab651e4d5b9895f1dab521ce52d0b0692 · Zeichen 873–1404 im Abschnitt